DAK:
<<Ahh, but we do hope they overreact!>>
For short term gain, YES. But, for bt portfolio performance and success, NO!
Now, many will talk how ENMD once rocketed from 10 to 85, and now dive from 25 to 5. And, this may be their excuse for avoiding bt sector or even short ones. Bad story hurt more than good one help, when is regular investor in consideration.
I do hope that at one point (and I think in near future) market and street will discover where are real value in bt sector. They may do simply by pocking around here at SI (for instance we wrote negatively about ENMD, who knows for how long) and capitalize on other bio-freaks work. For free.
Rick:
Thanks for explanation of my statement regards the BMY and Endostatin license option. BMY once show interest for thalidomide analogue, as anticancer agent, so they may knock on CELG doors too.
Miljenko
|
